Home » Faculty »  Adult Cardiothoracic Surgery »  Hassan Lemjabbar-Alaoui. Ph.D.

Hassan Lemjabbar-Alaoui, Ph.D.

Assistant Professor
Department of Surgery

Contact Information

2340 Sutter Street N-224, Box 1724
University of California, San Francisco
San Francisco, CA 94143-1724
415-476-9303 Phone
Hassan.Lemjabbar-Alaoui@ucsf.edu
  • University of Paris VII, B.S., Biology, 1988-1989
  • University of Paris VII, M.S.,  Molecular Biology and Immunology, 1989-1991
  • University of Paris VI, M.S., Biochemistry, 1991-1992
  • University of Paris VI, Post-Master University Diploma (DU), Clinical Pharmacokinetics and Therapeutics, 1992-1993
  • University of Paris XIII, Post-Master DE.A of Science, Medical and Biological Engineering, 1993-1994
  • University of Paris XII, Ph.D.,  Molecular and Cell Biology, 1994-1997
  • 1997-1998, Scientist, Naturalia Biologia. Paris, France
  • 1998-2001, Postdoctoral Researcher, Department of Anatomy, UCSF
  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery
  • Embryonic signaling pathways such as Wnt signaling
  • Role of the epidermal growth factor receptor (EGFR)
  • Sulf-1 and Sulf-2

Hassan Lemjabbar-Alaoui, Ph.D. is a biomedical scientist and Principal Investigator in the Thoracic Oncology Laboratory. Dr. Alaoui received his Ph.D. from the University of Paris XII.  Since receiving his Ph.D. from the University of Paris XII, he has been studying the epidermal growth factor receptor (EGFR), the reactivation of embryonic signaling pathways, and the roles these play in lung carcinogenesis.  Dr. Alaoui began these studies in 1997 as a postdoctoral fellow/Assistant Research Anatomist in Dr. Carol Basbaum's lab at UCSF, continued them as an Associate Research Anatomist in Steven Rosen's lab, and then as an Assistant Professor of Anatomy at UCSF. 

Dr. Alaoui's research is focused the role of the epidermal growth factor receptor (EGFR) in lung carcinogenesis as well as reactivation of embryonic signaling pathways such as Wnt signaling.The Alaoui Lab is a core component of the UCSF Thoracic Oncology Lab, Dr. Alaoui is currently investigating two extracellular regulators of Wnt signaling, Sulf-1 and Sulf-2, as new therapeutic targets and their role in promoting cell proliferation, survival, and angiogenesis, and in resistance to chemotherapy. Characterized a decade ago in the lab of Dr. Steven Rosen, these enzymes act on extracellular heparan sulfate. Sulfs remove specific internal sulfate residues from heparan sulfate proteoglycans (HSPGs) on both the cell surface and within the extracellular matrix.

 

Study ID: Rob test Sept 10 2013
 
Most recent publications from a total of 24
  1. Lemjabbar-Alaoui H, Hassan O, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015 Aug 18. View in PubMed
  2. Lemjabbar-Alaoui H, McKinney A, Yang YW, Tran VM, Phillips JJ. Glycosylation alterations in lung and brain cancer. Adv Cancer Res. 2015; 126:305-44. View in PubMed
  3. Singer MS, Phillips JJ, Lemjabbar-Alaoui H, Wang YQ, Wu J, Goldman R, Rosen SD. SULF2, a heparan sulfate endosulfatase, is present in the blood of healthy individuals and increases in cirrhosis. Clin Chim Acta. 2015 Feb 2; 440:72-8. View in PubMed
  4. Kim JH, Chan C, Elwell C, Singer MS, Dierks T, Lemjabbar-Alaoui H, Rosen SD, Engel JN. Endosulfatases SULF1 and SULF2 limit Chlamydia muridarum infection. Cell Microbiol. 2013 Sep; 15(9):1560-71. View in PubMed
  5. Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open. 2012; 2(6). View in PubMed
  6. Lemjabbar-Alaoui H, Sidhu SS, Mengistab A, Gallup M, Basbaum C. TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells. PLoS One. 2011; 6(3):e17489. View in PubMed
  7. Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets. 2010 Sep; 14(9):935-49. View in PubMed
  8. Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Basbaum C. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene. 2010 Jul 22; 29(29):4145-56. View in PubMed
  9. Uchimura K, Lemjabbar-Alaoui H, van Kuppevelt TH, Rosen SD. Use of a phage display antibody to measure the enzymatic activity of the Sulfs. Methods Enzymol. 2010; 480:51-64. View in PubMed
  10. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene. 2010 Feb 4; 29(5):635-46. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Hassan Lemjabbar-Alaoui, Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X